Eisai (company)
Japanese pharmaceutical company / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Eisai (company)?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.[2]
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Quick Facts Native name, Romanized name ...
Native name | エーザイ株式会社 |
---|---|
Romanized name | Ēzai kabushiki gaisha |
Company type | Public KK |
TYO: 4523 TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component | |
Industry | Pharmaceuticals |
Founded | December 6, 1941; 82 years ago (1941-12-06) |
Founder | Toyoji Naito |
Headquarters | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan |
Key people | Haruo Naito (President and CEO) |
Products | |
Revenue | ¥ 680 billion (2019)[1] |
¥ 103 billion (2019)[1] | |
¥ 72.5 billion (2019)[1] | |
Total assets | ¥ 1,071 billion (2019)[1] |
Total equity | ¥ 652 billion (2019)[1] |
Owner | The Master Trust Bank of Japan (11.78%) Japan Trustee Services Bank (10.99%) Nippon Life (4.29%)[1] |
Number of employees | 1,864 (2019)[1] |
Website | Official website |
Footnotes / references [citation needed] |
Close